Posted by Michael Wonder on 02 Jul 2016
Ticagrelor prevention after myocardial infarction: little additional benefit
1 June 2016 - The IQWIG has re-examined the benefits of the use of ticagrelor (Brilique) after acute coronary syndrome.
Ticagrelor was the the first medicine the IQWiG assessed under the AMNOG reforms in 2011. At that time it was found that the medicine provides a significant added value for patients with unstable angina. For heavier heart attacks, the medicine lacked supporting evidence.
The authorization of ticagrelor has since been extended: it can now be used in combination with low-dose aspirin in patients whose myocardial infarction dates back at least a year, namely the prevention of atherothrombotic events after one year of beginning treatment. The IQWiG has thus investigated whether the medicine has advantages over the appropriate comparator therapy for this indication. The agency has found there is an indication of an additional low additional benefit.
